Raymund R Razonable

List of Publications by Year
in descending order

206	10,421	26630 56	40979 93
papers	citations	h-index	g-index

216	216	216	9191
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Definitions of Cytomegalovirus Infection and Disease in Transplant Patients for Use in Clinical Trials: Table 1.. Clinical Infectious Diseases, 2017, 64, 87-91.	5.8	686
2	Cytomegalovirus in solid organ transplant recipientsâ€"Guidelines of the American Society of Transplantation Infectious Diseases Community of Practice. Clinical Transplantation, 2019, 33, e13512.	1.6	418
3	Outcomes from pandemic influenza A H1N1 infection in recipients of solid-organ transplants: a multicentre cohort study. Lancet Infectious Diseases, The, 2010, 10, 521-526.	9.1	329
4	Chromosomally integrated human herpesvirus 6: questions and answers. Reviews in Medical Virology, 2012, 22, 144-155.	8.3	320
5	Cytomegalovirus Infections in Solid Organ Transplantation: A Review. Infection and Chemotherapy, 2013, 45, 260.	2.3	249
6	Delayed-Onset Primary Cytomegalovirus Disease and the Risk of Allograft Failure and Mortality after Kidney Transplantation. Clinical Infectious Diseases, 2008, 46, 840-846.	5.8	233
7	Impact of cytomegalovirus infection, year of transplantation, and donor age on outcomes after liver transplantation for hepatitis C. Liver Transplantation, 2002, 8, 362-369.	2.4	223
8	Parvovirus B19 Infection after Transplantation: A Review of 98 Cases. Clinical Infectious Diseases, 2006, 43, 40-48.	5.8	216
9	Antiviral Drugs for Viruses Other Than Human Immunodeficiency Virus. Mayo Clinic Proceedings, 2011, 86, 1009-1026.	3.0	203
10	Clinical Utility of Viral Load in Management of Cytomegalovirus Infection after Solid Organ Transplantation. Clinical Microbiology Reviews, 2013, 26, 703-727.	13.6	179
11	New Developments in the Management of Cytomegalovirus Infection after Solid Organ Transplantation. Drugs, 2010, 70, 965-981.	10.9	178
12	Emergence of drugâ€resistant cytomegalovirus in the era of valganciclovir prophylaxis: therapeutic implications and outcomes. Clinical Transplantation, 2008, 22, 162-170.	1.6	158
13	The clinical use of various blood compartments for cytomegalovirus (CMV) DNA quantitation in transplant recipients with CMV disease. Transplantation, 2002, 73, 968-973.	1.0	144
14	Clinical Utility of Cytomegalovirus (CMV) Serology Testing in High-risk CMV D+/R- Transplant Recipients. American Journal of Transplantation, 2005, 5, 1065-1070.	4.7	142
15	Selective Reactivation of Human Herpesvirus 6 Variant A Occurs in Critically Ill Immunocompetent Hosts. Journal of Infectious Diseases, 2002, 185, 110-113.	4.0	137
16	Role of the Laboratory in Diagnosis and Management of Cytomegalovirus Infection in Hematopoietic Stem Cell and Solid-Organ Transplant Recipients. Journal of Clinical Microbiology, 2002, 40, 746-752.	3.9	137
17	Definitions of Resistant and Refractory Cytomegalovirus Infection and Disease in Transplant Recipients for Use in Clinical Trials. Clinical Infectious Diseases, 2019, 68, 1420-1426.	5.8	136
18	Relationship between Toll-Like Receptor 2 Polymorphism and Cytomegalovirus Disease after Liver Transplantation. Clinical Infectious Diseases, 2007, 44, 1315-1320.	5.8	133

#	Article	IF	Citations
19	Infections in liver transplant recipients. World Journal of Hepatology, 2011, 3, 83.	2.0	133
20	Polyomavirus Polymerase Chain Reaction as a Surrogate Marker of Polyomavirus-Associated Nephropathy. Transplantation, 2007, 84, 340-345.	1.0	124
21	Prosthetic Joint Infection Due to Rapidly Growing Mycobacteria: Report of 8 Cases and Review of the Literature. Clinical Infectious Diseases, 2007, 45, 687-694.	5.8	120
22	A Surveillance Study of Adenovirus Infection in Adult Solid Organ Transplant Recipients. American Journal of Transplantation, 2005, 5, 2555-2559.	4.7	118
23	Casirivimabâ€“Imdevimab treatment is associated with reduced rates of hospitalization among high-risk patients with mild to moderate coronavirus disease-19. EClinicalMedicine, 2021, 40, 101102.	7.1	116
24	Fluoride Excess and Periostitis in Transplant Patients Receiving Long-Term Voriconazole Therapy. Clinical Infectious Diseases, 2011, 52, 604-611.	5.8	114
25	Herpesvirus Infections in Solid Organ Transplant Patients at High Risk of Primary Cytomegalovirus Disease. Journal of Infectious Diseases, 2005, 192, 1331-1339.	4.0	109
26	Cytomegalovirus in Solid Organ Transplantation: Epidemiology, Prevention, and Treatment. Current Infectious Disease Reports, 2012, 14, 633-641.	3.0	107
27	Delayed-onset primary cytomegalovirus disease after liver transplantation. Liver Transplantation, 2007, 13, 1703-1709.	2.4	105
28	Effect of Preemptive Therapy vs Antiviral Prophylaxis on Cytomegalovirus Disease in Seronegative Liver Transplant Recipients With Seropositive Donors. JAMA - Journal of the American Medical Association, 2020, 323, 1378.	7.4	103
29	Epidemiology of cytomegalovirus disease in solid organ and hematopoietic stem cell transplant recipients. American Journal of Health-System Pharmacy, 2005, 62, S7-S13.	1.0	102
30	Dynamics of Cytomegalovirus Replication during Preemptive Therapy with Oral Ganciclovir. Journal of Infectious Diseases, 2003, 187, 1801-1808.	4.0	91
31	Cytomegalovirus. Microbiology Spectrum, 2016, 4, .	3.0	91
32	Human herpesvirus-6 infections in kidney, liver, lung, and heart transplantation: review. Transplant International, 2012, 25, 493-502.	1.6	89
33	Letermovir for the prevention of cytomegalovirus infection and disease in transplant recipients: an evidence-based review . Infection and Drug Resistance, 2019, Volume 12, 1481-1491.	2.7	88
34	The Pathogenesis of Hepatitis C Virus Is Influenced by Cytomegalovirus. Clinical Infectious Diseases, 2002, 35, 974-981.	5.8	85
35	New Developments in the Management of Cytomegalovirus Infection After Transplantation. Drugs, 2018, 78, 1085-1103.	10.9	84
36	The impact of human herpesvirus-6 and -7 infection on the outcome of liver transplantation. Liver Transplantation, 2002, 8, 651-658.	2.4	83

#	Article	IF	Citations
37	Critical care issues in patients after liver transplantation. Liver Transplantation, 2011, 17, 511-527.	2.4	81
38	Virologic Suppression Measured by a Cytomegalovirus (CMV) DNA Test Calibrated to the World Health Organization International Standard Is Predictive of CMV Disease Resolution in Transplant Recipients. Clinical Infectious Diseases, 2013, 56, 1546-1553.	5.8	79
39	Predictors of Immune Reconstitution Syndrome in Organ Transplant Recipients With Cryptococcosis: Implications for the Management of Immunosuppression. Clinical Infectious Diseases, 2015, 60, 36-44.	5.8	79
40	Treatment Considerations for COVID-19. Mayo Clinic Proceedings, 2020, 95, 1454-1466.	3.0	79
41	Urinary tract infections in kidney transplant recipients: Role of gender, urologic abnormalities, and antimicrobial prophylaxis. Annals of Transplantation, 2013, 18, 195-204.	0.9	79
42	Human herpesvirus 6 infections after liver transplantation. World Journal of Gastroenterology, 2009, 15, 2561.	3.3	78
43	Impact of urinary tract infection on allograft function after kidney transplantation. Clinical Transplantation, 2014, 28, 683-690.	1.6	78
44	GM-CSF Neutralization With Lenzilumab in Severe COVID-19 Pneumonia. Mayo Clinic Proceedings, 2020, 95, 2382-2394.	3.0	77
45	Real-World Clinical Outcomes of Bamlanivimab and Casirivimab-Imdevimab Among High-Risk Patients With Mild to Moderate Coronavirus Disease 2019. Journal of Infectious Diseases, 2021, 224, 1278-1286.	4.0	77
46	Secretion of Proinflammatory Cytokines and Chemokines during Amphotericin B Exposure Is Mediated by Coactivation of Toll-Like Receptors 1 and 2. Antimicrobial Agents and Chemotherapy, 2005, 49, 1617-1621.	3.2	73
47	Detection of simultaneous Î²-herpesvirus infections in clinical syndromes due to defined cytomegalovirus infection. Clinical Transplantation, 2003, 17, 114-120.	1.6	72
48	Comparative Quantitation of Cytomegalovirus (CMV) DNA in Solid Organ Transplant Recipients with CMV Infection by Using Two High-Throughput Automated Systems. Journal of Clinical Microbiology, 2001, 39, 4472-4476.	3.9	71
49	Use of Viral Load as a Surrogate Marker in Clinical Studies of Cytomegalovirus in Solid Organ Transplantation: A Systematic Review and Meta-analysis. Clinical Infectious Diseases, 2018, 66, 617-631.	5.8	67
50	A Longitudinal Molecular Surveillance Study of Human Polyomavirus Viremia in Heart, Kidney, Liver, and Pancreas Transplant Patients. Journal of Infectious Diseases, 2005, 192, 1349-1354.	4.0	65
51	Mycobacterium tuberculosis after solid organ transplantation: A review of more than 2000 cases. Clinical Transplantation, 2018, 32, e13259.	1.6	65
52	The impact of invasive fungal diseases on survival after lung transplantation. Clinical Transplantation, 2010, 24, 341-348.	1.6	64
53	Human Herpes Virus 8 in Solid Organ Transplantation. Transplantation, 2011, 92, 837-844.	1.0	63
54	Spectrum of early-onset and late-onset bacteremias after liver transplantation: Implications for management. Liver Transplantation, 2011, 17, 733-741.	2.4	63

#	Article	IF	Citations
55	Letermovir and inhibitors of the terminase complex: a promising new class of investigational antiviral drugs against human cytomegalovirus. Infection and Drug Resistance, 2015, 8, 269.	2.7	61
56	Homozygosity for the Toll-Like Receptor 2 R753Q Single-Nucleotide Polymorphism Is a Risk Factor for Cytomegalovirus Disease After Liver Transplantation. Journal of Infectious Diseases, 2012, 205, 639-646.	4.0	60
57	Management of cytomegalovirus infection and disease in liver transplant recipients. World Journal of Hepatology, 2014, 6, 370.	2.0	60
58	Monoclonal Antibody Therapy for COVID-19 in Solid Organ Transplant Recipients. Open Forum Infectious Diseases, 2021, 8, ofab255.	0.9	56
59	Reduction in False-Positive Aspergillus Serum Galactomannan Enzyme Immunoassay Results Associated with Use of Piperacillin-Tazobactam in the United States. Journal of Clinical Microbiology, 2014, 52, 2199-2201.	3.9	55
60	Cytomegalovirus infection in liver transplant recipients: Updates on clinical management. World Journal of Gastroenterology, 2014, 20, 10658.	3.3	53
61	Drug-resistant cytomegalovirus: clinical implications of specific mutations. Current Opinion in Organ Transplantation, 2018, 23, 388-394.	1.6	53
62	Rebound Phenomenon After Nirmatrelvir/Ritonavir Treatment of Coronavirus Disease 2019 (COVID-19) in High-Risk Persons. Clinical Infectious Diseases, 2023, 76, e537-e539.	5.8	53
63	Management Strategies for Cytomegalovirus Infection and Disease in Solid Organ Transplant Recipients. Infectious Disease Clinics of North America, 2013, 27, 317-342.	5.1	51
64	Donor derived Mycobacterium tuberculosis infection after solidâ€organ transplantation: A comprehensive review. Transplant Infectious Disease, 2018, 20, e12971.	1.7	51
65	Linezolid Therapy for Orthopedic Infections. Mayo Clinic Proceedings, 2004, 79, 1137-1144.	3.0	50
66	Epidemiology of invasive fungal infections in lung transplant recipients on longâ€term azole antifungal prophylaxis. Clinical Transplantation, 2015, 29, 311-318.	1.6	49
67	Clinical Diagnostic Testing for Human Cytomegalovirus Infections. Journal of Infectious Diseases, 2020, 221, S74-S85.	4.0	47
68	Valganciclovir for the prevention and treatment of cytomegalovirus disease in immunocompromised hosts. Expert Review of Anti-Infective Therapy, 2004, 2, 27-41.	4.4	45
69	The R753Q Polymorphism Abrogates Tollâ€Like Receptor 2 Signaling in Response to Human Cytomegalovirus. Clinical Infectious Diseases, 2009, 49, e96-e99.	5.8	45
70	A Framework for Outpatient Infusion of Antispike Monoclonal Antibodies to High-Risk Patients with Mild-to-Moderate Coronavirus Disease-19. Mayo Clinic Proceedings, 2021, 96, 1250-1261.	3.0	45
71	Clinical Features and Outcomes of Delayed-onset Primary Cytomegalovirus Disease in Cardiac Transplant Recipients. Journal of Heart and Lung Transplantation, 2007, 26, 1019-1024.	0.6	44
72	Clinical Significance of Pretransplant Chromosomally Integrated Human Herpesvirus-6 in Liver Transplant Recipients. Transplantation, 2011, 92, 224-229.	1.0	44

#	Article	IF	Citations
73	Fungal Infections After Lung Transplantation. Clinics in Chest Medicine, 2017, 38, 511-520.	2.1	44
74	A prospective longitudinal analysis of cytomegalovirus (CMV)-specific CD4+ and CD8+ T cells in kidney allograft recipients at risk of CMV infection. Transplant International, 2010, 23, 506-513.	1.6	42
75	Direct and indirect effects of cytomegalovirus: can we prevent them?. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2010, 28, 1-5.	0.5	42
76	Current concepts on cytomegalovirus infection after liver transplantation. World Journal of Hepatology, 2010, 2, 325.	2.0	42
77	Lemierre Syndrome Variant: Necrobacillosis Associated With Inferior Vena Cava Thrombosis and Pulmonary Abscesses After Trauma-Induced Leg Abscess. Mayo Clinic Proceedings, 2003, 78, 1153-1156.	3.0	40
78	Influence of Social and Cultural Factors on the Decision to Consent for Monoclonal Antibody Treatment among High-Risk Patients with Mild-Moderate COVID-19. Journal of Primary Care and Community Health, 2021, 12, 215013272110192.	2.1	40
79	Intravenous bamlanivimab use associates with reduced hospitalization in high-risk patients with mild to moderate COVID-19. Journal of Clinical Investigation, 2021, 131, .	8.2	40
80	Monoclonal Antibody Treatment of Breakthrough COVID-19 in Fully Vaccinated Individuals with High-Risk Comorbidities. Journal of Infectious Diseases, 2022, 225, 598-602.	4.0	40
81	Cidofovir Treatment of Progressive Multifocal Leukoencephalopathy in a Patient Receiving Highly Active Antiretroviral Therapy. Mayo Clinic Proceedings, 2001, 76, 1171-1175.	3.0	39
82	Strategies for managing cytomegalovirus in transplant recipients. Expert Opinion on Pharmacotherapy, 2010, 11, 1983-1997.	1.8	39
83	Relationship of Ganciclovir Therapeutic Drug Monitoring with Clinical Efficacy and Patient Safety. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	39
84	Absolute Lymphocyte Count Thresholds: A Simple, Readily Available Tool to Predict the Risk of Cytomegalovirus Infection After Transplantation. Open Forum Infectious Diseases, 2018, 5, ofy230.	0.9	37
85	<scp>HHV</scp>â€6 in liver transplantation: A literature review. Liver International, 2018, 38, 210-223.	3.9	36
86	Stimulation of toll-like receptor 2 with bleomycin results in cellular activation and secretion of pro-inflammatory cytokines and chemokines. Toxicology and Applied Pharmacology, 2006, 210, 181-189.	2.8	35
87	Impact of Gram-Negative Bloodstream Infection on Long-Term Allograft Survival After Kidney Transplantation. Transplantation, 2011, 91, 1206-1210.	1.0	34
88	Non-tuberculous mycobacterial infections in solid organ transplant recipients: An update. Journal of Clinical Tuberculosis and Other Mycobacterial Diseases, 2016, 4, 1-8.	1.3	34
89	Management of CMV infection and disease in transplant patients. 27-29 February 2004. Herpes: the Journal of the IHMF, 2004, 11, 77-86.	0.3	34
90	Epidemiology and risk factors for infection after living donor liver transplantation. Liver Transplantation, 2017, 23, 465-477.	2.4	32

#	Article	IF	Citations
91	Impact of human herpes virus 6 in liver transplantation. World Journal of Hepatology, 2010, 2, 345.	2.0	32
92	Comparison of Standardized Cytomegalovirus (CMV) Viral Load Thresholds in Whole Blood and Plasma of Solid Organ and Hematopoietic Stem Cell Transplant Recipients with CMV Infection and Disease. Open Forum Infectious Diseases, 2017, 4, ofx143.	0.9	31
93	Antifungal prophylaxis in lung transplant: A survey of United States' transplant centers. Clinical Transplantation, 2019, 33, e13630.	1.6	31
94	Nystatin Induces Secretion of Interleukin (IL)-1Î², IL-8, and Tumor Necrosis Factor Alpha by a Toll-Like Receptor-Dependent Mechanism. Antimicrobial Agents and Chemotherapy, 2005, 49, 3546-3549.	3.2	30
95	R753Q Single-Nucleotide Polymorphism Impairs Toll-Like Receptor 2 Recognition of Hepatitis C Virus Core and Nonstructural 3 Proteins. Transplantation, 2010, 89, 811-815.	1.0	30
96	Cytomegalovirus disease in solid organ transplant recipients: advances lead to new challenges and opportunities. Current Opinion in Organ Transplantation, 2007, 12, 610-617.	1.6	29
97	Management of viral infections in solid organ transplant recipients. Expert Review of Anti-Infective Therapy, 2011, 9, 685-700.	4.4	29
98	Clinical Correlation of Cytomegalovirus Infection With CMV-specific CD8+ T-cell Immune Competence Score and Lymphocyte Subsets in Solid Organ Transplant Recipients. Transplantation, 2019, 103, 832-838.	1.0	29
99	Safety considerations with current and emerging antiviral therapies for cytomegalovirus infection in transplantation. Expert Opinion on Drug Safety, 2019, 18, 1017-1030.	2.4	29
100	Breakthrough COVID-19 and casirivimab-imdevimab treatment during a SARS-CoV-2 B1.617.2 (Delta) surge. Journal of Clinical Virology, 2021, 145, 105026.	3.1	29
101	Immune-based therapies for cytomegalovirus infection. Immunotherapy, 2010, 2, 117-130.	2.0	28
102	Outcomes of bebtelovimab and sotrovimab treatment of solid organ transplant recipients with mildâ€toâ€moderate coronavirus disease 2019 during the Omicron epoch. Transplant Infectious Disease, 2022, 24, .	1.7	28
103	Cytomegalovirus (<scp>CMV</scp>) <scp>DNA</scp> quantification in bronchoalveolar lavage fluid of immunocompromised patients with <scp>CMV</scp> pneumonia. Clinical Transplantation, 2018, 32, e13149.	1.6	27
104	Infections and allograft rejection - intertwined complications of organ transplantation. Swiss Medical Weekly, 2005, 135, 571-3.	1.6	27
105	An assessment of interactions between hepatitis C virus and herpesvirus reactivation in liver transplant recipients using molecular surveillance. Liver Transplantation, 2007, 13, 1422-1427.	2.4	26
106	Immune response to CMV in solid organ transplant recipients: current concepts and future directions. Expert Review of Clinical Immunology, 2012, 8, 383-393.	3.0	26
107	The limits of refusal: An ethical review of solid organ transplantation and vaccine hesitancy. American Journal of Transplantation, 2021, 21, 2637-2645.	4.7	26
108	Herpesvirus infections in transplant recipients: current challenges in the clinical management of cytomegalovirus and Epstein-Barr virus infections. Herpes: the Journal of the IHMF, 2003, 10, 60-5.	0.3	26

#	Article	IF	Citations
109	A mobile unit overcomes the challenges to monoclonal antibody infusion for COVIDâ€19 in skilled care facilities. Journal of the American Geriatrics Society, 2021, 69, 868-873.	2.6	24
110	Clinical utility of cytomegalovirus viral load in solid organ transplant recipients. Current Opinion in Infectious Diseases, 2015, 28, 317-322.	3.1	23
111	Epidemiology of Cytomegalovirus Infection After Pancreas Transplantation. Transplantation, 2011, 92, 1044-1050.	1.0	22
112	Clinical Prioritization of Antispike Monoclonal Antibody Treatment of Mild to Moderate COVID-19. Mayo Clinic Proceedings, 2022, 97, 26-30.	3.0	22
113	Case Report: Capnocytophaga canimorsus A Novel Pathogen for Joint Arthroplasty. Clinical Orthopaedics and Related Research, 2009, 467, 1634-1638.	1.5	21
114	Editorial Commentary: Viridans Group Streptococci in Febrile Neutropenic Cancer Patients: What Should We Fear?. Clinical Infectious Diseases, 2014, 59, 231-233.	5.8	21
115	Risk factors for cytomegalovirus reactivation after liver transplantation: Can preâ€transplant cytomegalovirus antibody titers predict outcome?. Liver Transplantation, 2015, 21, 539-546.	2.4	21
116	A Collaborative Multidisciplinary Approach to the Management of Coronavirus Disease 2019 in the Hospital Setting. Mayo Clinic Proceedings, 2020, 95, 1467-1481.	3.0	21
117	Anti-Spike Monoclonal Antibody Therapy in Pregnant Women With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19). Obstetrics and Gynecology, 2022, 139, 616-618.	2.4	21
118	First-generation oral antivirals against SARS-CoV-2. Clinical Microbiology and Infection, 2022, 28, 1230-1235.	6.0	21
119	Infections due to human herpesvirus 6 in solid organ transplant recipients. Current Opinion in Organ Transplantation, 2010, 15, 671-675.	1.6	20
120	Chromosomally integrated human herpesvirus-6 in kidney transplant recipients. Nephrology Dialysis Transplantation, 2011, 26, 2391-2393.	0.7	20
121	Outcomes of COVID-19 With the Mayo Clinic Model of Care and Research. Mayo Clinic Proceedings, 2021, 96, 601-618.	3.0	20
122	Breakthrough COVIDâ€19 after SARSâ€CoVâ€2 vaccination in solid organ transplant recipients: An analysis of symptomatic cases and monoclonal antibody therapy. Transplant Infectious Disease, 2022, 24, .	1.7	20
123	Why do lung transplant patients discontinue triazole prophylaxis?. Transplant Infectious Disease, 2019, 21, e13067.	1.7	19
124	Absolute lymphocyte count as marker of cytomegalovirus and allograft rejection: Is there a â€œSafe Corridorâ€•after kidney transplantation?. Transplant Infectious Disease, 2021, 23, e13489.	1.7	19
125	Role of letermovir for prevention of cytomegalovirus infection after allogeneic haematopoietic stem cell transplantation. Current Opinion in Infectious Diseases, 2018, 31, 286-291.	3.1	18
126	Functional assessment of Toll-like receptor 2 and its relevance in patients with Staphylococcus aureus infection of joint prosthesis. Human Immunology, 2011, 72, 47-53.	2.4	17

#	Article	IF	Citations
127	Rare, unusual, and less common virus infections after organ transplantation. Current Opinion in Organ Transplantation, 2011, 16, 580-587.	1.6	17
128	Treatment of latent TB Infection and the risk of tuberculosis after solid organ transplantation: Comprehensive review. Transplant Infectious Disease, 2019, 21, e13178.	1.7	17
129	Antifungal prophylaxis in lung transplant recipients: A systematic review and metaâ€analysis. Transplant Infectious Disease, 2020, 22, e13333.	1.7	17
130	Effectiveness of Monoclonal Antibodies in Preventing Severe COVID-19 With Emergence of the Delta Variant. Mayo Clinic Proceedings, 2022, 97, 327-332.	3.0	17
131	Primary Cytomegalovirus Disease after Five Years of Antiviral Prophylaxis. Transplantation, 2006, 81, 137-138.	1.0	16
132	Misidentification of Neosartorya pseudofischeri as Aspergillus fumigatus in a Lung Transplant Patient. Journal of Clinical Microbiology, 2014, 52, 2722-2725.	3.9	16
133	COVID-19 and Solid Organ Transplantation: Role of Anti-SARS-CoV-2 Monoclonal Antibodies. Current Transplantation Reports, 2022, 9, 26-34.	2.0	16
134	A consensus conference to define the utility of advanced infectious disease diagnostics in solid organ transplant recipients. American Journal of Transplantation, 2022, 22, 3150-3169.	4.7	16
135	Î± Herpes Virus Infections Among Renal Transplant Recipients. Seminars in Nephrology, 2016, 36, 344-350.	1.6	15
136	Epidemiology, risk factors, and outcome of Clostridium difficile infection in heart and heartâ€lung transplant recipients. Clinical Transplantation, 2017, 31, e12968.	1.6	15
137	Application of a New Paradigm for Cytomegalovirus Disease Prevention in Mayo Clinicâ€™s First Face Transplant. Mayo Clinic Proceedings, 2019, 94, 166-170.	3.0	15
138	Virtual Recruitment Is Here to Stay: A Survey of ID Fellowship Program Directors and Matched Applicants Regarding Their 2020 Virtual Recruitment Experiences. Open Forum Infectious Diseases, 2021, 8, ofab383.	0.9	15
139	Toll-like receptor 2 polymorphism and Gram-positive bacterial infections after liver transplantation. Liver Transplantation, 2011, 17, n/a-n/a.	2.4	14
140	Immune-based monitoring for cytomegalovirus infection in solid organ transplantation: is it ready for clinical primetime?. Expert Review of Clinical Immunology, 2014, 10, 1213-1227.	3.0	14
141	Pharmacologic and immunologic management of cytomegalovirus infection after solid organ and hematopoietic stem cell transplantation. Expert Review of Clinical Pharmacology, 2018, 11, 773-788.	3.1	14
142	Prevention and treatment of tuberculosis in solid organ transplant recipients. Expert Review of Anti-Infective Therapy, 2020, 18, 63-73.	4.4	14
143	An update on Mycobacterium tuberculosis infection after hematopoietic stem cell transplantation in adults. Clinical Transplantation, 2018, 32, e13430.	1.6	12
144	Innate immune genetic profile to predict infection risk and outcome after liver transplant. Hepatology, 2010, 52, 814-821.	7.3	11

#	Article	IF	Citations
145	Long-term Outcomes of Patients With Human Herpesvirus 6 Encephalitis. Open Forum Infectious Diseases, 2019, 6, ofz269.	0.9	11
146	A Fatal Case of Disseminated Microsporidiosis Due to Anncaliia algerae in a Renal and Pancreas Allograft Recipient. Open Forum Infectious Diseases, 2019, 6, ofz285.	0.9	11
147	Predictors of CMV Infection in CMV-Seropositive Kidney Transplant Recipients: Impact of Pretransplant CMV-Specific Humoral Immunity. Open Forum Infectious Diseases, 2021, 8, ofab199.	0.9	11
148	Avoiding a Medical Education Quarantine During the Pandemic. Mayo Clinic Proceedings, 2020, 95, S63-S65.	3.0	10
149	The Impact of Antifungal Prophylaxis in Lung Transplant Recipients. Annals of the American Thoracic Society, 2021, 18, 468-476.	3.2	10
150	Cytomegalovirus in Solid Organ Transplant Recipients: Clinical Updates, Challenges and Future Directions. Current Pharmaceutical Design, 2020, 26, 3497-3506.	1.9	9
151	Cytomegalovirus infection after liver transplantation. Liver Transplantation, 2010, 16, S45-S53.	2.4	8
152	Prolonged shedding of pandemic influenza A (H1N1) 2009 virus in a pancreas-after-kidney transplant recipient. Journal of Clinical Virology, 2014, 61, 302-304.	3.1	8
153	Treatment of cytomegalovirus infection and disease preâ€•and postâ€quantitative nucleic acid test standardization: does use of a more sensitive assay lead to longer treatment duration?. Clinical Transplantation, 2016, 30, 154-160.	1.6	8
154	Mycoplasma hominis vertebral spine infection: Case report and a review of infections of bone and joints. Journal of Infection and Chemotherapy, 2016, 22, 755-758.	1.7	8
155	Epidemiology, risk factors, and outcomes of infections in patients undergoing liver transplantation for hilar cholangiocarcinoma. Clinical Transplantation, 2017, 31, e13023.	1.6	8
156	Travelerâ€™s Diarrhea Recommendations for Solid Organ Transplant Recipients and Donors. Transplantation, 2018, 102, S35-S41.	1.0	8
157	Differences in Duration and Degree of Cytomegalovirus DNAemia Observed With Two Standardized Quantitative Nucleic Acid Tests and Implications for Clinical Care. Journal of Infectious Diseases, 2020, 221, 251-255.	4.0	8
158	Fungal Infection in Lung Transplantation. Seminars in Respiratory and Critical Care Medicine, 2021, 42, 471-482.	2.1	8
159	Outcomes of B-Cell-Depleted Patients With Coronavirus Disease 2019 Treated With Antispike Monoclonal Antibodies. Open Forum Infectious Diseases, 2022, 9, .	0.9	8
160	Not the Usual Viral Suspects: Parvovirus B19, West Nile Virus, and Human T-Cell Lymphotrophic Virus Infections After Kidney Transplantation. Seminars in Nephrology, 2016, 36, 428-434.	1.6	6
161	Evaluation of COBAS AmpliPrep/COBAS TaqMan CMV Test for use in hematopoietic stem cell transplant recipients. Expert Review of Molecular Diagnostics, 2017, 17, 633-639.	3.1	6
162	Prosthetic Joint Infections Due to Histoplasma capsulatum: A Report of 3 Cases. Mayo Clinic Proceedings Innovations, Quality & Outcomes, 2021, 5, 225-229.	2.4	6

#	Article	IF	Citations
163	Unexpected Cytomegalovirus (CMV) Replication Kinetics in CMV Donor-Seropositive, Recipient-Seronegative Liver Transplant Recipients Receiving Preemptive Antiviral Therapy. Journal of Infectious Diseases, 2022, 225, 436-442.	4.0	6
164	Successful Liver Transplantation From a SARS-CoV-2 Positive Donor to a Positive Recipient. Transplantation, 2022, Publish Ahead of Print, .	1.0	6
165	LB21. Preemptive Therapy (PET) vs. Prophylaxis for Prevention of Cytomegalovirus (CMV) Disease in High-Risk Donor Seropositive/Recipient Seronegative (D+Râ¯) Liver Transplant Recipients (LTR): A NIH-Sponsored, Randomized, Controlled, Multicenter Trial. Open Forum Infectious Diseases, 2018, 5, S766-S766.	0.9	5
166	A survey of infection prevention and control practices among solid organ transplantation centers. American Journal of Infection Control, 2019, 47, 101-104.	2.3	5
167	Cytomegalovirus-related Complications and Management in Facial Vascularized Composite Allotransplantation: An International Multicenter Retrospective Cohort Study. Transplantation, 2022, 106, 2031-2043.	1.0	5
168	Valganciclovir for the treatment of cytomegalovirus retinitis in patients with AIDS. Expert Review of Ophthalmology, 2007, 2, 351-361.	0.6	4
169	HHV-6A and HHV-6B in Solid Organ Transplantation. , 2014, , 201-215.		4
170	Clinical Guidance and the Delivery of Care for Patients With Coronavirus Disease 2019. Mayo Clinic Proceedings, 2020, 95, S23-S25.	3.0	4
171	Education of Infectious Diseases Fellows During the COVID-19 Pandemic Crisis: Challenges and Opportunities. Open Forum Infectious Diseases, 2021, 8, ofaa583.	0.9	4
172	Rates of Severe Outcomes After Bamlanivimab-Etesevimab and Casirivimab-Imdevimab Treatment of High-Risk Patients With Mild to Moderate Coronavirus Disease 2019. Mayo Clinic Proceedings, 2022, 97, 943-950.	3.0	4
173	In replyâ€"The â€œPerfect Cytokine Stormâ€•of COVID-19. Mayo Clinic Proceedings, 2020, 95, 2037-2038.	3.0	3
174	Rapid Appraisal System for COVID-19 Medical Information. Mayo Clinic Proceedings, 2020, 95, S26-S28.	3.0	3
175	Risk Factors for Cytomegalovirus Viremia following Liver Transplantation With a Seropositive Donor and Seronegative Recipient Receiving Antiviral Therapy. Journal of Infectious Diseases, 2021, 223, 1073-1077.	4.0	3
176	A tale of two unusual anaerobic bacterial infections in an immunocompetent man: A case report and literature review. Anaerobe, 2021, 71, 102416.	2.1	3
177	Anti-infective chemoprophylaxis after solid-organ transplantation. Expert Review of Clinical Immunology, 2018, 14, 469-479.	3.0	2
178	Casirivimab-Imdevimab Treatment Is Associated with Reduced Rates of Hospitalization Among High-Risk Patients with Mild to Moderate Coronavirus Disease-19. SSRN Electronic Journal, 0, , .	0.4	2
179	Infection prevention and control considerations for safe outpatient monoclonal antibody infusions in patients with coronavirus disease 2019 (COVID-19). Infection Control and Hospital Epidemiology, 2021, , 1-2.	1.8	2
180	Transient Hepatitis B Surface Antigenemia Following Immunization with Heplisav-B. Mayo Clinic Proceedings Innovations, Quality & Outcomes, 2021, 5, 542-547.	2.4	2

#	Article	IF	Citations
181	Reply to Puing et al. Journal of Infectious Diseases, 2021, , .	4.0	2
182	Individualized management of cytomegalovirus in solid organ transplant recipients. Expert Review of Precision Medicine and Drug Development, 2021, 6, 333-344.	0.7	2
183	Cytomegalovirus Infection After Solid Organ Transplantation. , 2016, , 441-475.		2
184	Association of HHV-6 With Outcomes in CMV-Seronegative Liver Transplant Recipients With CMV-Seropositive Donors Receiving Preemptive Antiviral Therapy. Transplantation, 2020, Publish Ahead of Print, 2427-2434.	1.0	2
185	Twice as nice: Cytomegalovirus teleâ€education. Transplant Infectious Disease, 2022, 24, .	1.7	2
186	1426Correlation of Cytomegalovirus Viral Load between a Laboratory-Developed Test and a WHO-Calibrated Commercial Assay in Transplant Recipients. Open Forum Infectious Diseases, 2014, 1, S375-S375.	0.9	1
187	Cytomegalovirus DNA in Transplant Recipients: Comparison of Whole Blood and Plasma Viral Loads. Open Forum Infectious Diseases, 2016, 3, .	0.9	1
188	Progress Toward HHV-8 Prevention After Transplantation. Transplantation, 2017, 101, 1751-1752.	1.0	1
189	A rare manifestation of CMV disease in a kidney transplant recipient. Transplant Infectious Disease, 2021, 23, e13527.	1.7	1
190	Cytomegalovirus Infection in Transplantation. , 0, , 129-167.		1
191	JC Virus Infection After Transplantation: Beyond the Classic Progressive Multifocal Leukoencephalopathy?. Gastroenterology and Hepatology, 2007, 3, 74-6.	0.1	1
192	Immune reconstitution inflammatory syndrome in a nonâ€HIV immunocompromised patient with Pneumocystis Jirovecii pneumonia. Transplant Infectious Disease, 2022, 24, .	1.7	1
193	Patient Perspectives on Anti-spike Monoclonal Antibody Therapy for Mild to Moderate Coronavirus Disease-2019. Journal of Patient Experience, 2022, 9, 237437352211056.	0.9	1
194	Stewardship of COVID-19 volunteers by nested trial design. Lancet Infectious Diseases, The, 2022, 22, 1400-1401.	9.1	1
195	Reply to â€œMay the Indirect Effects of CIHHV-6 in Transplant Patients be Exerted Through the Reactivation of the Viral Replicative Machinery?â€. Transplantation, 2011, 92, e51-e52.	1.0	0
196	1174Comparing the Duration of Treatment for Cytomegalovirus Infection Pre and Post Quantitative Nucleic Acid Test Standardization: Does Use of a More Sensitive Assay Lead to Longer Treatment Duration?. Open Forum Infectious Diseases, 2014, 1, S350-S350.	0.9	0
197	Survey of Infection Prevention and Control (IPAC) Practices among Kidney and Liver Transplant Centers. Open Forum Infectious Diseases, 2016, 3, .	0.9	0
198	Utilization of Quantiferon-Cytomegalovirus Assay to Assess the Risk of CMV Disease and Guide Duration of Antiviral Prophylaxis in CMV-Mismatched Solid Organ Transplant Recipients. Open Forum Infectious Diseases, 2016, 3, .	0.9	0

#	Article	IF	Citations
199	Epidemiology and Risk Factors for Infection after Living Donor Liver Transplantation (LDLT). Open Forum Infectious Diseases, 2016, 3, .	0.9	0
200	Survey of Infection Prevention and Control (IPAC) Practices among Heart and Lung Transplant Centers. Open Forum Infectious Diseases, 2016, 3, .	0.9	0
201	Cytomegalovirus (CMV) Deoxyribonucleic Acid (DNA) Quantification in Bronchoalveolar Lavage Fluid Collected From Immunocompromised Patients With CMV Pneumonia. Open Forum Infectious Diseases, 2016, 3, .	0.9	0
202	How do we treat human herpesvirus 6 infection after allogeneic hematopoietic stem cell transplantation?. Future Virology, 2017, 12, 85-88.	1.8	0
203	Herpes Simplex Viruses 1 and 2, Varicella Zoster Virus, and Human Herpes Viruses 6, 7, and 8 in Transplant Recipients. , 2019, , 667-677.		0
204	Fungal Infection and Prevention in Lung Transplant. Current Fungal Infection Reports, 2021, 15, 136-142.	2.6	0
205	Toll-Like Receptors: Novel Molecular Targets for Antiviral Immunotherapy. , 0, , 333-346.		0
206	Early CMV Infection Detected By Quantitative Nucleic Acid Testing (QNAT) Is Associated with Lower Risk of Relapse after Reduced Intensity, but Not Myeloablative, Hematopoietic Cell Transplantation in Acute Myeloid Leukemia. Blood, 2015, 126, 1913-1913.	1.4	0